Shanghai Kai Kai Industry Past Earnings Performance
Past criteria checks 4/6
Shanghai Kai Kai Industry has been growing earnings at an average annual rate of 23%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 2.5% per year. Shanghai Kai Kai Industry's return on equity is 9.8%, and it has net margins of 5.2%.
Key information
23.0%
Earnings growth rate
22.5%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | 2.5% |
Return on equity | 9.8% |
Net Margin | 5.2% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Shanghai Kai Kai Industry Company Limited's (SHSE:600272) 31% Jump Shows Its Popularity With Investors
Jul 24Shanghai Kai Kai Industry's (SHSE:600272) Weak Earnings May Only Reveal A Part Of The Whole Picture
Apr 05Some Shanghai Kai Kai Industry Company Limited (SHSE:600272) Shareholders Look For Exit As Shares Take 27% Pounding
Feb 28Revenue & Expenses Breakdown
How Shanghai Kai Kai Industry makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 1,024 | 53 | 155 | 0 |
31 Mar 24 | 960 | 53 | 169 | 0 |
31 Dec 23 | 925 | 39 | 169 | 0 |
30 Sep 23 | 813 | 26 | 188 | 0 |
30 Jun 23 | 748 | 28 | 189 | 0 |
31 Mar 23 | 915 | 41 | 196 | 0 |
31 Dec 22 | 894 | 40 | 196 | 0 |
30 Sep 22 | 879 | 48 | 160 | 0 |
30 Jun 22 | 871 | 45 | 168 | 0 |
31 Mar 22 | 657 | 29 | 143 | 0 |
31 Dec 21 | 670 | 22 | 160 | 0 |
30 Sep 21 | 661 | 15 | 154 | 0 |
30 Jun 21 | 704 | 16 | 149 | 0 |
31 Mar 21 | 743 | 13 | 155 | 0 |
31 Dec 20 | 762 | 14 | 147 | 0 |
30 Sep 20 | 818 | 13 | 153 | 0 |
30 Jun 20 | 823 | 14 | 166 | 0 |
31 Mar 20 | 825 | 17 | 170 | 0 |
31 Dec 19 | 870 | 22 | 167 | 0 |
30 Sep 19 | 875 | 23 | 193 | 0 |
30 Jun 19 | 875 | 25 | 176 | 0 |
31 Mar 19 | 887 | 34 | 171 | 0 |
31 Dec 18 | 878 | 35 | 177 | 0 |
30 Sep 18 | 889 | 45 | 142 | 0 |
30 Jun 18 | 937 | 44 | 161 | 0 |
31 Mar 18 | 947 | 41 | 140 | 0 |
31 Dec 17 | 962 | 39 | 143 | 0 |
30 Sep 17 | 961 | 27 | 169 | 0 |
30 Jun 17 | 927 | 26 | 156 | 0 |
31 Mar 17 | 913 | 23 | 168 | 0 |
31 Dec 16 | 906 | 21 | 166 | 0 |
30 Sep 16 | 891 | 16 | 165 | 0 |
30 Jun 16 | 890 | 21 | 170 | 0 |
31 Mar 16 | 887 | 20 | 168 | 0 |
31 Dec 15 | 881 | 20 | 163 | 0 |
30 Sep 15 | 884 | 10 | 148 | 0 |
30 Jun 15 | 877 | 5 | 144 | 0 |
31 Mar 15 | 890 | 1 | 150 | 0 |
31 Dec 14 | 883 | 36 | 146 | 0 |
30 Sep 14 | 893 | 55 | 130 | 0 |
30 Jun 14 | 885 | 55 | 139 | 0 |
31 Mar 14 | 876 | 57 | 140 | 0 |
31 Dec 13 | 859 | 25 | 135 | 0 |
30 Sep 13 | 828 | 15 | 139 | 0 |
Quality Earnings: 600272 has a large one-off gain of CN¥71.2M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: 600272's current net profit margins (5.2%) are higher than last year (3.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600272's earnings have grown significantly by 23% per year over the past 5 years.
Accelerating Growth: 600272's earnings growth over the past year (91.2%) exceeds its 5-year average (23% per year).
Earnings vs Industry: 600272 earnings growth over the past year (91.2%) exceeded the Pharmaceuticals industry -0.6%.
Return on Equity
High ROE: 600272's Return on Equity (9.8%) is considered low.